Managed care considerations: vulnerable populations and prevention strategies for respiratory syncytial virus disease.
Peskin
Steven R
SR
The Chatham Institute, Chatham, New Jersey, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use; D003245:Consensus Statements as Topic; D006801:Humans; D007223:Infant; D008329:Managed Care Programs; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control*; D012307:Risk Factors; D012621:Seasons; D014481:United States / Q000453:epidemiology; D035862:Vulnerable Populations
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab